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Neurobiology of Disease
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One of the current challenges of neurodegenerative disease research is to determine whether signaling pathways that are essential to
cellular homeostasis might contribute to neuronal survival and modulate the pathogenic process in human disease. In Caenorhabditis
elegans, sir-2.1/SIRT1 overexpression protects neurons from the early phases of expanded polyglutamine (polyQ) toxicity, and this
protection requires the longevity-promoting factor daf-16/FOXO. Here, we show that this neuroprotective effect also requires the DAF-
16/FOXO partner bar-1/-catenin and putative DAF-16-regulated gene ucp-4, the sole mitochondrial uncoupling protein (UCP) in
nematodes. These results fit with a previously proposed mechanism in which the -catenin FOXO and SIRT1 proteins may together
regulate gene expressionand cell survival. Knockdownof-catenin enhanced the vulnerability to cell deathofmutant-huntingtin striatal
cells derived from the HdhQ111 knock-in mice. In addition, this effect was compensated by SIRT1 overexpression and accompanied by
the modulation of neuronal UCP expression levels, further highlighting a cross-talk between -catenin and SIRT1 in the modulation of
mutantpolyQcytoxicity. Taken together, these results suggest that integrationof-catenin, sirtuin andFOXOsignalingprotects fromthe
early phases of mutant huntingtin toxicity.
Introduction
Huntington’s disease (HD) is a dominantly inheritedCAG repeat
disorder with expanded polyglutamine (polyQ) tracts in hun-
tingtin (htt), causing striatal and cortical degeneration (Walker,
2007). While a person carrying more than 39 CAG repeats will
invariably develop HD, the age at onset of HD varies consider-
ably. The CAG expansions account for about 60% of the variabil-
ity of the age at onset of HD, and the residual variability may be
heritable, suggesting that other genes influence age at onset (Li et
al., 2003; Gaya´n et al., 2008; Metzger et al., 2008; Taherzadeh-
Fard et al., 2009; Xu et al., 2009). Given that HD is an age-related
disorder, candidate gene approaches based on longevity modula-
tors have been examined to identify disease modifiers. Studies of
TCERG1, an evolutionary conserved transcriptional regulator
that modulates longevity in Caenorhabditis elegans (Ghazi et al.,
2009), showed that this protein is neuroprotective in models of
HD (Arango et al., 2006) and that its polymorphic Gln-Ala repeat
modifiesHD inAmerican patients (Holbert et al., 2001). Another
longevity modulator with neuroprotective activities is the tran-
scription factor daf-16/FOXO. FOXO proteins are essential for
stress resistance (Brunet et al., 2004), and daf-16 is required for
neuroprotection by increased dosage of sirtuin sir-2.1/SIRT1 in
expanded-polyQ nematodes (Parker et al., 2005). Several cofac-
tors regulate FOXO activity, and FOXOs have many targets
(Greer and Brunet, 2008; Landis and Murphy, 2010; Yen et al.,
2011), suggesting that a network of genes centered onto FOXO
might regulatemutant polyglutamine neuron survival and have a
role in HD variability. Interestingly, in this regard FOXO activity
may be conserved fromC. elegans to humans, as humanFOXO3A
was associated with the ability to be long lived in several popula-
tions of centenarians (Willcox et al., 2008; Anselmi et al., 2009; Li
et al., 2009; Soerensen et al., 2010). Here, we investigated the
neuroprotective role of theWnt effector BAR-1/-catenin, a pro-
tein that also binds to DAF-16/FOXO3a to regulate its transcrip-
tional activity in response to oxidative stress in both C. elegans
and mammalian cells (Essers et al., 2005), and that of ucp-4, the
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sole mitochondrial uncoupling protein (UCP) in C. elegans and
putative DAF-16 transcriptional target. To this end, we used C.
elegans transgenics expressing exon-1 like htt in touch receptor
neurons (Parker et al., 2005). Animals expressing expanded
polyQs show a strong neuronal dysfunction phenotype (defective
response to touch) in the absence of cell death (Parker et al.,
2005), recapitulating an early phase of mutant htt neurotoxicity.
Additionally, we tested for the effects of SIRT1, -catenin, and
neuronal UCPs (UCP2, UCP4) on the survival of striatal cells
derived from htt knock-in mice (Trettel et al., 2000). As detailed
below, our results suggest that integration of -catenin, sirtuin,
and FOXO signaling protects against the early phases of mutant
htt toxicity.
Materials andMethods
Nematode experiments. Thewild-type strain ofC. elegans usedwas Bristol
N2. Standard methods of culturing and handling worms, either her-
maphrodites or males, were used. All strains were scored at 20°C. Touch
tests, scoring of PLM cell processes, drug response assays, and quantita-
tive real-time PCRwere performed as described previously (Parker et al.,
Table 1. Names and genotypes of the C. elegans strains used in this study
Name Genotypea Origin
Bristol N2 Standard wild type CGCb
TJ356 zIs356pdaf-16::daf-16-gfp; rol-6IV CGC
CB1370 daf-2(e1370)III CGC
GR1307 daf-16(mgDf50)I CGC
HT1890 daf-16(mgDf50)I;daf-2(e1370)III CGC
CF1038 daf-16(mu86)I CGC
EW15 bar-1( ga80)X CGC
CY121 ucp-4(ok195)V CGC
LG100 geIn3sir-2.1; rol-6; dyf-(?) L. Guarente (MIT, Boston, MA)
ID1280c geIn3sir-2.1; rol-6 This study
ID245d igIs245mec-3p::htt57–19Q::CFP; lin-15();mec-7p::YFP See Parker et al., 2005
ID1d igIs1mec-3p::htt57–128Q::CFP; lin-15();mec-7p::YFP Parker et al., 2005
ID191d igIs245mec-3p::htt57–19Q::CFP; lin-15();mec-7p::YFP; bar-1( ga80)X This study
ID1281d igIs1mec-3p::htt57–128Q:CFP; lin-15();mec-7p::YFP; bar-1( ga80)X This study
ID192d igIs245mec-3p::htt57–19Q::CFP; lin-15();mec-7p::YFP; ucp-4(ok195)V This study
ID1282d igIs1mec-3p::htt57–128Q::CFP; lin-15();mec-7p::YFP; ucp-4(ok195)V This study
ID1283d igIs245mec-3p::htt57–19Q::CFP; lin-15();mec-7p::YFP; sir-2.1(ok434)X This study
ID1285d igIs1mec-3p::htt57–128Q::CFP; lin-15();mec-7p::YFP; sir-2.1(ok434)X This study
ID1286d igIs1mec-3p::htt57–128Q::CFP; lin-15();mec-7p::YFP; daf-16(mgDf50)I This study
ID1287d igIs1mec-3p::htt57–128Q::CFP; lin-15();mec-7p::YFP; geIn3sir-2.1; rol-6 This study
ID1288d igIs1mec-3p::htt57–128Q::CFP; lin-15();mec-7p::YFP; geIn3sir-2.1; rol-6; bar-1( ga80)X This study
ID1289d igIs1mec-3p::htt57–128Q::CFP; lin-15();mec-7p::YFP; geIn3sir-2.1; rol-6; ucp-4(ok195)V This study
ID1290d igIs245mec-3p::htt57–19Q::CFP; lin-15();mec-7p::YFP; sir-2.1(ok434)X; igEx500mec-3p::sir-2.1-biGFP This study
ID1291d igIs1mec-3p::htt57–19Q::CFP; lin-15();mec-7p::YFP; sir-2.1(ok434)X; igEx501mec-3p::sir-2.1-biGFP This study
ID1292d igIs1mec-3p::htt57–128Q::CFP; lin-15();mec-7p::YFP; sir-2.1(ok434)X; igEx502mec-3p::sir-2.1-biGFP This study
ID1293d igIs1mec-3p::htt57–128Q::CFP; lin-15();mec-7p::YFP; sir-2.1(ok434)X; igEx503mec-3p::sir-2.1-biGFP This study
ID1296d igIs1mec-3p::htt57–128Q::CFP; lin-15();mec-7p::YFP; sir-2.1(ok434)X; igEx506mec-3p::GFP This study
ID1297d igIs1mec-3p::htt57–128Q::CFP; lin-15();mec-7p::YFP; sir-2.1(ok434)X; igEx507mec-3p::GFP This study
ID1298 igEx508ucp-4p::ucp-4::mCherry;myo-2p::GFP This study
ID1299 igEx509ucp-4p::ucp-4::mCherry;myo-2p::GFP This study
ID1300 igEx510ucp-4p::ucp-4::mCherry;myo-2p::GFP; zIs356 This study
ID1301 igEx511ucp-4p::ucp-4::mCherry;myo-2p::GFP; zIs356 This study
ID1302e igEx512ucp-4pWT::mCherry;myo-2p::GFP This study
ID1303e igEx513ucp-4pWT::mCherry;myo-2p::GFP This study
ID1304e igEx514ucp-4pWT::mCherry;myo-2p::GFP; daf-16(mu86)I This study
ID1305e igEx515ucp-4pWT::mCherry;myo-2p::GFP; daf-16(mu86)I This study
ID1306e igEx516ucp-4pWT::mCherry;myo-2p::GFP; zIs356 This study
ID1307e igEx517ucp-4pWT::mCherry;myo-2p::GFP; zIs356 This study
ID1308e igEx518ucp-4pSCR::mCherry;myo-2p::GFP This study
ID1309e igEx519ucp-4pSCR::mCherry;myo-2p::GFP This study
ID1310e igEx520ucp-4pSCR::mCherry;myo-2p::GFP; daf-16(mu86)I This study
ID1311e igEx521ucp-4pSCR::mCherry;myo-2p::GFP; daf-16(mu86)I This study
ID1312e igEx522ucp-4pSCR::mCherry;myo-2p::GFP; zIs356 This study
ID1313e igEx523ucp-4pSCR::mCherry;myo-2p::GFP; zIs356 This study
ID1314d igIs1mec-3p::htt57–128Q::CFP; lin-15();mec-7p::YFP; bar-1( ga80)X; igEx524mec-3p::bar-1-bi-mCherry;myo-2p::GFP This study
ID1315d igIs1mec-3p::htt57–128Q::CFP; lin-15();mec-7p::YFP; bar-1( ga80)X; igEx525mec-3p::bar-1-bi-mCherry;myo-2p::GFP This study
ID1316d igIs1mec-3p::htt57–128Q::CFP; lin-15();mec-7p::YFP; bar-1( ga80)X; igEx526mec-3p::mCherry;myo-2p::GFP This study
ID1317d igIs1mec-3p::htt57–128Q::CFP; lin-15();mec-7p::YFP; bar-1( ga80)X; igEx527mec-3p::mCherry;myo-2p::GFP This study
aAll mutant strains were outcrossed at least three times before use except for extrachromosomal arrays.
bCaenorhabditis Genetics Center (University of Minnesota, Minneapolis, MN).
cThe ID1280 strain contains the transgene from the original strain LG100 andwas outcrossed 10 times (see Materials andMethods). It does not contains the dyfmutation, present in the original LG1 00, and shows no dye-filling defect (see
the Results section).
dhtt57 refers to amino acids 1–57 of human huntingtin.
eWT refers to the ucp-4wild-type promoter. SCR refers to the ucp-4 promoter with the DAF-16 binding motif scrambled (see Materials and Methods).
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2005). Western analysis was performed using standard protocols and htt
fusion proteins detected with the GFP antibody ab6556 (Abcam). Muta-
tions and transgenes used in this study are listed in Table 1. All strains
were obtained from the C. elegans Genetics Center (University of Min-
nesota, Minneapolis, MN), except for those generated in the laboratory.
For strain construction with polyQ transgenes, mutants were verified by
visible phenotypes, deletion mutants by PCR analysis, point mutations
by sequencing, or a combination thereof. Deletion mutants were out-
crossed aminimum of three times to wild type, and the geIs3[sir-2.1()]
strain was outcrossed 10 times to wild type before use. The geIs3[sir-
2.1()] animals were tested for dye-filling defect as described previously
(Burnett et al., 2011) and showed no defect in this regard.
To test for rescue of the effects of sir-2.1 loss of function (LOF) in
128Q animals, constructs encoding SIR-2.1 were generated as follows.
We assembled the sir-2.1 cDNA with a bicistronic GFP (biGFP) by
PCR fusion. We obtained the sir-2.1 cDNA from wild-type animals by
RT-PCR, using RV197 (5-GGGGACAACTTTGTATACAAAAGTTG
ATGTCACGTGATAGTGGCAAC-3) and RV198 (5-GTGAAAGT
AGGATGAGACAGCTCAGATACGCATTTCTTCAC-3) primers.
RV198 contains a sequence complementary to the 5 region of biGFP.
We amplified biGFP from pAN51 using RV192 (5-GCTGTCTCAT
CCTACTTTCAC) and RV178 (5-GGGGACCACTTTGTA CAAGAA
AGCTGGGTATTATAGTTCATCCATGCCATGTGTA-3). Then, we
fused both PCR products by nested PCR using primers RV197 and
RV178. These primers contain the sequences of attB5 and attB2, re-
spectively, for recombination in the pDONR221-P5-P2 vector using
the Gateway system (Invitrogen). In parallel, we produced a clone in
pDONR221-P1-P5r containing the promoter of mec-3, mec-3p using
primersRV3 (5-GGGGACAAGTTTGTACAAAAAAGCAGGCTCCT
GCAGGTACCCGGAGTAGTTG-3)andRV4(5-GGGGACAACTTT
TGTATA CAAAGTTGTGGCGCGCCAATGCGCGAAATTGTGGC
TACTC-3). Both clones were used to assemble mec-3p and sir-2.1-
biGFP using Gateway technology in the destination vector pDEST-
AN, which is suitable for C. elegans transgenesis.
To test for rescue of the effects of bar-1 LOF in 128Q animals, constructs
encoding BAR-1 were generated as follows. We assembled the bar-1 cDNA
with a bicistronic mCherry (bi-mCherry) by PCR fusion. We obtained the
bar-1 cDNA from wild-type animals by RT-PCR using RV229 (5-GGGG
ACAACTTTGTATACAAAAGTTGATGGAC CTGGATCCGAACCTAG-
3)andRV230(5-GTGAAAGTAGGATGAGACAGCTTAAAATCGACTA
TTCCTAGAAG-3)primers.RV230contains a sequencecomplementary to
the 5 region of bi-mCherry.We amplified bi-mCherry from the pGEM-T-
bicistronic mCherry construct using RV192 (5-GCTGTCTCATCCTACT
TTCAC-3) and the universal primer SP6. Then, we fused both PCR
products by nested PCR using primers RV229 and RV8 (5-GGGGACCA
CTTTGTACAAGAAAGCTGGGTATTATTTGTATAGTTCATCCATGCC
ACC-3). These primers contain respectively attB5 and attB2 sequences for
recombination in the pDONR221-P5-P2 vector using the Gateway system
(Invitrogen). We combined the resulting construct with the plasmid
pDONR221-P1-P5r (which containsmec-3p) to generate the bar-1 overex-
pression construct by means of the Gateway technology in the destination
vector pDEST-AN, which is suitable forC. elegans transgenesis.
Constructs for mCherry expression under the control of the UCP-4 pro-
moter (1768bp)weregeneratedas follows.We fused thepromoterofUCP-4
(fromposition1768bpupstreamof theATGofucp-4) and theucp-4gene to
mCherry::unc-54Terminator. Primers used to amplify ucp-4 were Forward
5-TTTTGCGTTTGCTCGTCGCAC-3andReverse5-AGTCGACCTGCA
GGCATGCAAGCT-3.WeamplifiedmCherry fromaplasmidgeneratedby
replacing GFP from pPD95.75 by mCherry and by using the primers For-
ward 5-AGCTTGCATGCCTGCAGGTCGACT-e and Reverse 5-GGAA
ACAGTTATGTTTGGTATATTGGG-3. Constructs encoding mCherry
under the control of the ucp-4 promoter (1768 bp), either wild-type or
scrambled at binding site 2, were generated as follows. We amplified the
promoter of ucp-4 (from position 1768 bp upstream of the ATG of ucp-4)
and cloned PCR fragments into pRV10 (a derivative of pPD95.75, in which
GFP has been substituted by mCherry). Primers used to amplify the ucp-4
promoter sequencewere Forward 5-GGGGAAGCTTTTTTGCGTTTGCT
CGTCGCAC-3 and Reverse 5-GGGG CCCGGGCATCTGAATAAAAG
TTATAATTCC-3. Primers used tomutagenizeDAF-16 binding site 2were
Forward 5-AAATACATGTTTGATTCTTTTTGAATACAGCTGTGACG
TAA-3 and Reverse 5-GCTGTATTCAAAAAGAATCAAACATGTATTT
AAATACATTTG-3 (the scrambled sequence is underlined). All of these
constructs were verified for sequence integrity.
For transgenesis, 5–20ng/lDNAof the constructswas injected into 19Q
and 128Q nematodes, together with pPD118.33 (a plasmid containing
myo-2p::GFP), at a final total DNA concentration of 100–150 ng/l using
standard methods. We isolated at least two independent strains from each
construct to perform the touch tests. Strains stably expressing the UCP-4-
mCherry reporter were crossed to the wild-type N2 strain or to a strain
overexpressing a translational construct encodingDAF-16::GFP (TJ356, in-
sertion zIs356IV) (Henderson and Johnson, 2001), and animals homozy-
gous for each allele (w/w, daf-16::GFP/daf-16::GFP) were isolated. Similar
crosses were performed using strains stably expressing mCherry under the
control of the ucp-4 promoter, which carried a wild-type or scrambled
DAF-16bindingsite2.ThemCherry signalswere scoredblindlyusingaZeiss
fluorescence microscope (10), and quantification was performed using
NIH ImageJ.
Touch tests involved scoring for the response to a light touch at the tail
by using a fine hair. Touch tests were performed blindly by scoring 10
touches at the tail of the young adult animal for a minimum of 200
animals per genotype (50–60 animals per independent experiment for a
total of at least 4 independent experiments). Touch tests in strains ex-
pressing extrachromosomal arrays involved a minimum of 60 animals
per array (20–30 animals per independent experiment for a total of at
least 3 independent experiments). Ordinarily, wild-type animals will re-
spond by backing away from the touch. The responses were recorded for
every animal such that, for example, 3 responses out of 10 at the tail is
given as 30% responsiveness, and the mean values for responsiveness
were retained for comparison of nematode groups. Although nematodes
become habituated after 30 touch stimuli, restricting analysis to 10
touch challenges ensures that no significant habituation occurs within
this range (Giles and Rankin, 2009). Axonal aggregation and axonal
swelling were scored as described previously (Parker et al., 2005) by
testing a minimum of 100 animals per treatment. The primers used for
quantitative (q)RT-PCR analysis of htt transgene expression were For-
ward 5-CACTTGTCACTACTTTCTCAT-3 and Reverse 5-GTAGTT
CCCGTCATCTTTG-3, with the primers Forward 5-CTTCTGCAAG
GGATCTGCTAAG-3 and Reverse 5-GATTTGGAGCTGGGTTGACT
TC-3 used for amplification of the housekeeping gene col-1 as a control.
Proteins were extracted from whole animals as described previously
(Parker et al., 2005), separated by SDS-PAGE, and analyzed by Western
blotting using mouse anti-htt (GenScript A00089, 1:500) and mouse
anti-actin (MP Biomedicals, 1:10,000). Secondary antibodies were goat
anti-mouse IgG HRP conjugated (Bio-Rad). Proteins were detected us-
ing ECL and evaluated by densitometry using a GS-800 densitometer
(Bio-Rad), and quantification was performed using ImageJ.
Chromatin immunoprecipitation (ChIP) was performed as described
previously (Oh et al., 2006; Mukhopadhyay et al., 2008) using a DAF-16
antibody generated against the C-terminal portion of DAF-16a2 (Oh et
al., 2006) and wild-type (N2), daf-2(e1370), daf-16(mgDf50), and daf-
16(mgDf50);daf-2(e1370) worms. Binding on ChIP samples was deter-
mined by real-time PCR using the following primers: binding site 1,
tctgtgtcagcagcttttcg and acggccgtccgtaatagata; binding site 2, tgagcaagtt-
gtaatggggtta and catctggcacttatggggtta; and 3 region, aaccaggagcac-
cattcaac and gcaacttcttcctgctgacc.
Mammalian experiments. Cell death assays for HdhQ111 mouse striatal
cells expressing full-length htt with either wild-type (7Q/7Q) or mutant
(109Q/109Q) polyglutamines were performed as described previously, with
cell death induced by one-day serum deprivation (Arango et al., 2006). We
used jetPEI for transfection with cDNA and jetSI-ENDO for transfection
with RNAmolecules as indicated by the manufacturer (PolyPlus Transfec-
tion). The siRNAs (si-htt, si--catenin, si-SIRT1, si-SIRT2, si-SIRT3, si-
UCP2, si-UCP4) and scramble RNAswere obtained fromQIAGEN. Except
forhtt, forwhich siRNAshavebeendescribed (DiFiglia et al., 2007),mixesof
3–4 different siRNA sequences per gene (25 or 33 nM) were systematically
tested for modulation of cell survival and siRNA target gene expression,
followed by the evaluation of individual siRNA sequences at optimal con-
centration(25–100nM).Effectsoncell survivalwere considered tobe reliable
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if two different siRNAs showed similar effects on target mRNA/protein ex-
pression and cell survival and if scrambled RNAs (25–100 nM) did not show
any effect. The active siRNA sequences shown in figures are as follows: htt
siRNA, 5- TTCATCAGCTTTTCCAGGGTC-3 (100 nM); -catenin
siRNA,5-GGCTTTTCCCAGTCCTTCATT-3 (100nM);SIRT1siRNA,5-
GATTGTTATTAATATCCTTTT-3(25nM);SIRT2siRNA5-TTGGGTGA
AGTTCTATTTGTT-3 (25 nM); SIRT3 siRNA,
5-TTACCGATCAACATGCTAGTT-3 (25
nM); UCP2 siRNA, 5–GAAGAACGAGACAC
CTTTA-3 (33 nM); and UCP4 siRNA 5-CG
CCATTTACAGACAGGTA-3 (33 nM). The
corresponding scramble RNAs were as it fol-
lows: htt, 5-GTCCAGATTTCCCTGTCGTA
T-3 (100 nM); -catenin, 5-GCTCTCGCCA
TATGAATCTCT-3 (100 nM); SIRT1, 5-GT
TTATGCTCATTATATAT-3 (25 nM); SIRT2
5-GTTAGTTAGTTCGTGTAGT-3 (25 nM);
SIRT3, 5-GCTATGTATCAGCACACTA-3
(25 nM); UCP2, 5-GCATAAGACCGACAAT
AGT-3 (33 nM); and UCP4, 5-GAGCCATCA
ACTGACTAGT-3 (33 nM). The construct
encoding an active variant of SIRT1 (2 kb
cDNA) lacking an internal segment in the N
terminuswas pCDNA3.1-sirt1-Flag. Cells were
subjected to DAPI staining, and cell death was
scored 48 h after cell transfection by counting
pyknotic versus normal nuclei in DAPI-and JetSI-
ENDO-positivecells.Cytoplasmicandnuclearpro-
teins were extracted as described previously
(Arango et al., 2006), separated by SDS-PAGE, and
analyzed by Western blotting using the following
primary antibodies: mouse anti-SIRT1 (Millipore,
1:1000), mouse anti-SIRT2 (Santa Cruz Bio-
technology, 1:100), rabbit anti-SIRT-3 (Ab-
gent, 1:100), rabbit anti--catenin (Cell
Signaling Technology, 1:5000), goat anti-
UCP2 (Santa Cruz Biotechnology, dilution),
rabbit anti-UCP4 (Abcam, 1:25), mouse anti-htt
(4C8, Millipore Bioscience Research Reagents,
1:5000 or GenScript A00089, 1:500), mouse
anti-actin (Invitrogen, 1:2000), rabbit anti-
NCAM (Millipore Bioscience Research Re-
agents, 1:10,000). Secondary antibodies were
goat anti-mouse IgG HRP-conjugated and
goat anti-rabbit IgG HRP-conjugated (Bio-
rad). Proteins were detected using ECL and
evaluated by densitometry using a GS-800 densi-
tometer (Bio-Rad), and quantification was per-
formed using ImageJ. Chemicals were purchased
from Calbiochem [6-bromoindirubin-3-oxime
(BIO) andLiCl].
RNAIsolationandquantitativeRT-PCR in stri-
atal cells. Quantitative RT-PCR was performed
on RNA extracted from 109Q/109Q mouse stri-
atal cells transfectedwith the appropriate siRNAs
and scramble RNAs to assess gene silencing effi-
ciency. Two days after cell transfection, RNAwas
extracted with a Qiagen RNeasy kit and Dnase I
(Sigma) treatment (as per the manufacturer’s
protocol). Single-strand cDNA synthesis was
doneusingoligo(dT), randomhexamerpriming,
and 100 ng of total RNA with ABsolute 2-Step
QRT-PCR SYBR ROX kit (ABgene). Quantita-
tive PCR was performed using SYBRGreen with
theABI PRISM7700 SequenceDetection System
(Applied Biosystems) and oligonucleotides as
follows:ucp2-f(5-TCCTGCTACCTCCCAGAA
GA-3), ucp2-r (5-TGAGACCTCAAAGCAG
CCTC-3),ucp4-f(5-GTGACGCCCGCCATTT
ACAG-3),ucp4-r(5-CATCCCTCCAATGACC
GATTTCC-3), sirt2-f (5-CCCTTCGCCTCCCTCATC-3), sirt2-r (5-GT
CCCTGTAAGCCTTCTTGG-3),sirt3-f(5-TGGCTGACTTCGCTTTGG-
3),sirt3-r(5-TCCACACCATGAACTACATCC-3),rpl13a-f(5-CTGCTG
CTCTCAAGGTTGTTC-3), rpl13a-r (5-CTGCTTCTTCTTCCGATAGT
GC-3), hprt-f (5-TTTGCCGCGAGCCG-3), hprt-r (5-TAACCTGGTT
Figure 1. -Catenin and ucp-4 are required for neuroprotection by sir-2.1 in 128Q nematodes. A, bar-1/-catenin null muta-
tion enhanced touch insensitivity at the tail of 128Q nematodes. No changewas detected in 19Q animals. ***p 0.001 compared
to 128Q alone. B, ucp-4 deletion enhanced 128Q neuronal dysfunction. No change was detected in 19Q animals. ***p 0.001
compared to 128Q alone. C, 128Q transgene expression is unchanged at the protein andmRNA levels in 128Q nematodes bearing
bar-1 or ucp-4 LOF. D, Aggravation of neuron dysfunction by sir-2.1 LOF (sir-2.1(ok434 )) was suppressed in animals specifically
overexpressing (O/E) wild-type SIR-2.1 in touch receptor neurons under the control of the promoter of the mec-3 gene with no
effect detected in animals overexpressing empty vector (ID1296 and ID1297; see Table 1). Aggravation of neuron dysfunction by
bar-1 LOF (bar-1( ga80)) was suppressed in animals specifically overexpressing wild-type BAR-1 in touch receptor neurons under
the control of the promoter of themec-3gene,with no effect detected in detected in animals overexpressing empty vector (ID1316
and ID1317; see Table 1). Shown are data compiled from two independent extrachromosomal arrays per genotype. ***p 0.001
versus empty vector. n.s., Not significant. E, Neuroprotection by increased Sir2 dosage (sir-2.1(O/E)) against 128Q toxicity was lost
in animals mutant for bar-1 or ucp-4. *p 0.001 versus 128Q; **p 0.001 versus sir-2.1(O/E) alone. Data in A, B, and E are
meansSEMwith	200animals per genotype (50–60animals per independent experiment for a total of at least 4 independent
experiments). Data for touch tests in strains expressing extrachromosomal arrays (D) are means SEM with	60 animals per
array (20–30 animals per independent experiment for a total of at least 3 independent experiments).
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CATCATCGCTAATC-3). Assays and data
analysis were performed according to themanu-
facturer’s protocol (User Bulletin #2, ABI PRISM
7700 Sequence Detection System, PerkinElmer).
All samples were run at least in triplicate using
rpl13a or hprt as the calibrator gene with a dilu-
tion of 1/100 of cDNA. The amount of target,
normalized to an endogenous reference (ucp2 or
ucp4) and relative to the calibrator (rpl13a or
hprt), was calculated using the 2
CT method,
and statistical significance was determined using
paired t tests.
Statistics. Statistics of nematode data were
performed using one-way ANOVA, with cor-
rection for multiple testing by Tukey’s Multi-
ple Comparison Test. Data were expressed as
mean SEM for	60–200 nematodes in each
group, depending on the experiments per-
formed (see figure legends). Student’s t tests
were used for striatal cell data. Data were ex-
pressed as mean  SD for 	150 cells in each
group. Student’s t test was used for gene and
protein expression data. All experiments were
repeated at least three times. p 0.05 was con-
sidered significant.
Results
-Catenin and ucp-4 are required for
neuroprotection by increased sir-2.1
dosage in C. elegans
Nematodes expressing normal (19Q)
polyQs in touch receptor neurons show a
moderate loss of response to touch,whereas
nematodes bearing an expanded (128Q)
polyQ show a strong loss of response to
touch (85%). This touch phenotype is ac-
companied by axonal swelling and, impor-
tantly, occurs in the absence of cell death
(Parker et al., 2005), providing an in vivo
model tomanipulate the early phases of ex-
panded polyQ neurotoxicity.
We previously reported that the sir-2.1/
SIRT1-daf-16/FOXO pathway is neuro-
protective in expanded polyQ nematodes
(Parker et al., 2005). Importantly, we
showed that the neuroprotective effects of
sir-2.1 overexpression in these animals is
unrelated to background mutations that
may produce dye-filling defects and influ-
ence lifespan in C. elegans (Burnett et al.,
2011), and the sir-2.1 overexpresser strain
used herein does not show dye-filling de-
fects. Recent work in C. elegans has sug-
gested that for DAF-16 to gain specificity in
the regulation of lifespan and other biologi-
cal processes,DAF-16may interactwithdif-
ferent cofactors (Wolff et al., 2006; Landis
andMurphy, 2010; Yen et al., 2011). There-
fore, to further investigate the regulation of
neuronal survival by sir-2.1/SIRT1-daf-16/
FOXO, we first examined the evolutio-
nary conserved FOXO cofactor BAR-1/-
catenin. BAR-1/-catenin directly interacts
with both DAF-16 and FOXO3a and has
been shown to have a role in oxidative stress
Figure2. TheUCP-4 promoter is regulated byDAF-16.A, DAF-16binds to theUCP-4 promoter. The 5 region of UCP-4 has three
consensus DAF-16 binding sites (top; only 2 sites are shown; binding site 1 has two closely located consensus sites) that are
separated by 3.7 kb. One of the binding sites is located 894 bp upstream of the ATG (binding site 2), while two others are located
4.655 and 4.964 kb upstream of ATG. Since the latter sites are closely situated, primers were designed for the site at 4.655 kb
(binding site 1). Primers were also designed for region 654 bp downstream of the stop codon as a control site in the 3-region.
Chromatin immunoprecipitation (bottom) using anti-DAF-16 antibody (bottom) using N2, daf-2(e1370), daf-16(mgDf50), and
daf-16(mgDf50);daf-2(e1370). The binding was normalized to that of N2, and effects for which p 0.01 were considered signif-
icant. *p 0.005 compared to N2. B, Representative images for DAF-16 overexpression to increase the activity of the UCP-4
promoter (1768bp) in late L4C. elegansnematodesas inferred fromquantifying the intensity ofmCherry signals in thepharynx (see
Results). C, The effects of DAF-16 on the activity of the ucp-4 promoter requires binding site 2. Constructs encodingmCherry under
the control of the ucp-4 promoter (1768 bp),which carried awild-type (ucp-4pWT) or scrambled (ucp-4p SCR) binding site 2,were
stably expressed inN2,daf-16(mu86 ) or TJ356 strain, andmCherry signalswerequantified as indicated inB. Data aremeanSEM
as compiled from two independent arrays (SL1, SL2) per genotype, and	60 animals per array (20–30 animals per independent
experiment for a total of at least 3 independent experiments).
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signaling (Essers et al., 2005). Loss of function of bar-1 enhanced the
loss of response to touch in 128Qnematodes with no effect detected
in 19Q nematodes (Fig. 1A) and no change detected in 128Q trans-
gene expression (Fig. 1C), indicating that bar-1 protects from neu-
ron dysfunction induced by expanded polyQs.
Next, we examined a putative DAF-16 target gene, ucp-4, to
expand on how daf-16might affect neuronal survival. The ucp-4
gene encodes for the sole mitochondrial uncoupling protein,
UCP, in C. elegans (Iser et al., 2005). We tested ucp-4 for two
reasons. First, UCPs might be transcriptional targets of FOXO as
suggested by a bioinformatics survey of DAF-16 binding sites in
the C. elegans genome (Lee et al., 2003) and a transcriptome
analysis of Foxo3a-null mouse neural stem cells (Paik et al.,
2009). Second, UCPs are thought to be essential to neuron sur-
vival and neurodegenerative disease pathogenesis (Andrews et
al., 2005b). Deletion of ucp-4 resulted in enhanced neuronal dys-
function in 128Q animals with no effect in 19Q animals (Fig. 1B)
and no change detected in 128Q transgene expression (Fig. 1C),
indicating that ucp-4 protects from neuron dysfunction induced
by expanded polyQs.
In the 128Q nematodes, neuronal dysfunction is intrinsically
connected to the dosage of sir-2.1 (Parker et al., 2005; Burnett et
al., 2011). Neuron dysfunction is aggravated by sir-2.1 LOF
(Parker et al., 2005), and this effect is rescued by overexpression
of wild-type sir-2.1 in mechanosensory neurons with no effect of
empty vector control, suggesting that this effect of sir-2.1 LOF is
cell-autonomous (Fig. 1D). The aggravation of neuron dysfunc-
tion by LOF of bar-1 in 128Q nematodes (Fig. 1A) is also cell
autonomous, as suggested by the rescue of this effect by overex-
pression of wild-type bar-1 in mechanosensory neurons with no
effect of empty vector control (Fig. 1D). In contrast to aggrava-
tion by sir-2.1 LOF, increased sir-2.1 dosage is neuroprotective
and requires daf-16 (Parker et al., 2005). Therefore we tested how
the DAF-16 cofactor bar-1 and the putative DAF-16 target ucp-4
may also be required for this neuroprotective activity of sir-2.1.
The increase in touch response induced by sir-2.1 overexpression
was lost in 128Q animals bearing either a bar-1 or a ucp-4 LOF
mutation, and the detrimental effects of bar-1 LOF and ucp-4
LOF on touch response were similar in 128Q nematodes and
128Q nematodes bearing increased sir-2.1 dosage (Fig. 1E). To-
gether, these results indicated that the neuroprotective effect of
sir-2.1 in addition to requiring daf-16 is also dependent on bar-1
and ucp-4.
The ucp-4 promoter is regulated by DAF-16
Having shown that ucp-4 is required for sir-2.1 to regulate ex-
panded polyQ toxicity in C. elegans neurons, we next tested
whether the ucp-4 gene, a putativeDAF-16 target (Lee et al., 2003;
Paik et al., 2009), may be directly regulated by DAF-16. We
scanned the promoter of ucp-4 and identified 3 consensus
DAF-16 binding sites within 5 kb upstream of the translation
start site (Fig. 2A). We then isolated whole worm extracts from
mix staged populations of wild-type (N2), as well as animals mu-
tant for daf-2/IR-IGF1R or daf-16/FOXO or both, and we per-
formed ChIP with an anti-DAF-16 antibody to test for DAF-16
direct binding to the ucp-4 promoter (Oh et al., 2006; Mukho-
padhyay et al., 2008). There was no statistically significant differ-
ence in binding signals for the binding site 1 and the 3 region
in daf-16mutant animals, signifying DAF-16 independent re-
cruitment (Fig. 2A). In contrast, binding signals were strongly
decreased for binding site 2 when DAF-16 was absent, signi-
fying DAF-16 dependence (Fig. 2A). To test for the functional
role of binding site 2, we generated C. elegans transgenic
strains stably expressing mCherry under the control of the
ucp-4 promoter (1768 bp fragment), which carried a wild-type
or scrambled DAF-16 binding site 2, and we crossed these
strains into a DAF-16 protein overexpression or daf-16 knock-
out background. First, constructs encoding UCP-4::mCherry un-
der the control of the ucp-4 promoter were stably expressed in a
wild-type N2 strain or a strain overexpressing DAF-16::GFP
(translational construct TJ356), and the intensity ofmCherry sig-
nals was quantified in late L4 animals in the pharynx area, an area
where DAF-16 isoforms and UCP-4 are known to be expressed
(Lee et al., 2001; Lin et al., 2001) using two independent arrays
per genotype and 	60 animals per array (20–30 animals per
independent experiment for a total of at least 3 independent ex-
periments). The expression of mCherry was increased (p 
0.005) in animals bearingDAF-16 overexpression (mean SEM:
40  2.7, arbitrary unit) compared to wild-type (mean  SEM:
57  2.8, arbitrary unit) (see also Fig. 2B). Second, mCherry
expression required DAF-16 binding site 2, as shown by the loss
of variation of mCherry expression in animals bearing either
daf-16 LOF or DAF-16 overexpression when the ucp-4 promoter
carried a scrambled sequence for this binding site (Fig. 2C). To-
gether, these experiments suggested that the ucp-4 promotermay
be regulated by DAF-16.
Figure 3. The GSK-3 inhibitor BIO is neuroprotective via FOXO signaling in 128Q nema-
todes. A, Neuron dysfunction in 128Q nematodes is higher compared to 19Q nematodes, with
about 85% of the 128Q animals having a defective response to touch (Parker et al., 2005). BIO
strongly rescues expanded polyQ neurotoxicity at 100–33.3M (*p 0.001 and **p 0.01
versus DMSO controls) with no effect in 19Q animals. BIO rescuing activity was lost in mutants
for daf-16, sir-2.1, bar-1, and ucp-4. Dilution factor is 3. Percent rescue was calculated from
percentages of touch response as ((test
 control)/(100
 control) * 100). Data aremeans
SEMwith	200 animals per point for all genotypes (50–60 animals per independent experi-
ment for a total of at least 4 independent experiments). The percentages of touch response
(means SEM)were 52 3% in 19Q animals treatedwith vehicle, 23 2% in 128Q animals
treated with vehicle, 46 3% in 128Q animals treated with 100M BIO, and 34.6 4% in
128Q animals treated with 33.3M BIO. B, BIO reduced axonal swelling in PLM cells of 128Q
animals (*p 0.002 versus DMSO controls). Data are means SEM with	100 animals per
treatment (25–30 animals per independent experiment for a total of at least 4 independent
experiments). C, BIO treatment (50M, 100M) does notmodify transgene expression in 128Q
nematodes. n.s., Not significant.
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GSK-3 inhibitors require bar-1, sir-2.1, daf-16, and ucp-4 for
neuroprotection
To further expand the mechanistic basis for neuroprotection by
sir-2.1 in connection with daf-16 and bar-1 activities, we sought
to look at the regulation of -catenin, a protein that is part of the
Wnt signaling pathway and is primarily targeted for degradation
by direct phosphorylation by the GSK-3 kinase. Interestingly,
previous studies on a simple model system have shown GSK-3
inhibitors such as lithium may protect from expanded polyQs
(Berger et al., 2005; Voisine et al., 2007), suggesting that GSK-3
inhibitors may be useful for HD therapy. Therefore, we tested
whether sir-2.1, daf-16, bar-1, and ucp-4 may be required for
neuroprotection by GSK-3 inhibitors. We first tested BIO, a
selective inhibitor of GSK-3, and observed that at 100–30 M
BIO significantly reduced neuron dysfunction in 128Q animals
with no effect detected in 19Q animals (Fig. 3A) and no change
detected in 128Q transgene expression (Fig. 3C). However, neu-
roprotection by BIO was lost in 128Q nematode mutant for any
of the four genes including sir-2.1, daf-16, bar-1 and ucp-4 (Fig.
3A), indicating these genes are required for BIO activity. BIO also
reduced axonal swelling (Fig. 3B), which may reflect increased
neuron health and is consistent with the ability of BIO to reduce
the loss of touch response in 128Q nematodes. We also tested
lithium chloride, a drug that has GSK-3 inhibition properties,
and observed neuroprotective effects similar to those of BIO
(data not shown). While BIO and lithium may have secondary
targets other than GSK-3, a genome-scale functional RNAi
screen indicated that gsk-3 inactivation is neuroprotective in
expanded-polyQ nematodes (Lejeune et al., 2012), suggesting
that the neuroprotective effects of BIO and lithium may involve
theGSK-3 target. Together, these results suggested that the neu-
roprotective properties of GSK-3 inhibitors require sir-2.1, daf-
16, bar-1, and ucp-4, which may be useful for protecting HD
neurons from the dysfunction induced by mutant polyQs.
-Catenin, SIRT1 overexpression, and UCPsmodulate the
survival of mouse striatal cells
Having shown that sir-2.1, bar-1, and ucp-4modulate the neuro-
toxicity of a N-terminal htt fragment in nematodes, we tested
whether their mammalian counterparts may have an effect in a
full-length cellular model of HD. To this end, we used striatal
cells derived from the htt knock-in mice HdhQ111 (Trettel et al.,
2000).Mutant htt (109Q/109Q) striatal cells have a higher rate of
cell death induced by serum deprivation compared to wild-type
Figure4. -CateninandUCP2/UCP4modulate the survival ofmutanthtt striatal cells fromHdhQ111mice. In theseassays, cellswere subjected to serumdeprivation.A, Representativegraphshowing that
109Q/109Qcellsweremore susceptible to cell deathcompared to7Q/7Qcells (N3withSD;*p0.01compared to7Q/7Q).B, Effectsof reducinghtt levels.Htt siRNAreduced109Q/109Qcellmortality (N
3with SD; **p 0.001 versus untreated). Scramble RNA showed no effect. ns, Not significant. C, RepresentativeWestern blot showing that Htt siRNA treatment reduces Htt expression levels in 7Q/7Q and
109Q/109Qstriatalcells. Inthefollowingpanels,dataarenormalizedduetothevariabilityofstriatalcell survivalafterserumdeprivationacrossexperiments.D,Effectsof reducing-catenin levelsandofBIO(0.5
M) treatment. Left,-Catenin siRNAenhanced109Q/109Qcellmortality (N3withSD; *p0.01versusuntreated). ScrambleRNAshowednoeffect. BIO treatment reduced cellmortality (N3withSD;
**p 0.05 versus DMSO controls).When-catenin siRNA andBIOwere combined, no change in cellmortalitywas detected compared to cells treatedwith scramble RNA andDMSO (N 3with SD). Right,
-catenin siRNA and BIO showed no effect in 7Q/7Q cells. E, Mutant htt expressionwas unchanged by treatment with BIO or-catenin siRNA.-Catenin levels are increased by BIO (N 3, p 0.02) and
reduced by-catenin siRNA (n 3, p 0.05). Scramble RNAhadno effect.E, Effects of reducing SIRT1, UCP2, andUCP4 (N 4with SD). UCP2 siRNAenhanced 109Q/109Q cellmortality (*p 0.01 versus
untreated)withnoeffectdetected in7Q/7Qcells.UCP4siRNA reduced109Q/109Qcellmortality (*p0.01versusuntreated)withnoeffectdetected in7Q/7Qcells. ScrambleRNAshadnoeffect.G,Mutanthtt
expressionwas unchangedby siRNAs against SIRT1, UCP2, andUCP4. Shownare representativeWestern blots. Scramble RNAs showednoeffect.H, At left is a representativeWestern blot image showing that
109Q/109Q cells have lower SIRT1 levels upon SIRT1 siRNA treatment (N 3; p 0.05). Quantitative RT-PCR experiments indicated that UCP2 and UCP4 siRNA decreased mRNA levels of UCP2 and UCP4,
respectively(N5withSD;p0.05).TheeffectofUCP2/4siRNAsontargetproteinexpressioncouldnotbeevaluated,astheantiserawererepeatedlyunabletodetectanyprotein inWesternblotexperiments,
and scramble RNAs showedno effect. For all panels,N indicates the number of independent experiments performed.
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(7Q/7Q) cells (Trettel et al., 2000), thus providing an assay to test
for cell vulnerability tomutant htt expressed at endogenous levels
(Fig. 4A). To test for the implication of htt in cell death induced
by serum deprivation, we subjected these cells to htt siRNA treat-
ment using a previously described siRNA (DiFiglia et al., 2007) and
corresponding scrambled RNA. Reducing htt levels in 109Q/109Q
cells strongly decreased cell mortality upon serumdeprivation, with
no change detected in 7Q/7Qcells (Fig. 4B), suggesting that a signif-
icantpercentof cellmortality is associated tomutant htt expression.
As reported previously (Gines et al., 2003), mutant htt cells
showed increased -catenin levels (data not shown) that may
correspond to a prosurvival response (Gines et al., 2003). To test
for the role of-catenin in striatal cell survival, we subjected these
cells to -catenin siRNA treatment (see Materials and Methods
for details of siRNA experiments). Reducing -catenin levels de-
creased the survival of 109Q/109Qcells, an effect accompanied by
reduction of -catenin expression, and no change in htt expres-
sionwas detected (Fig. 4C,D). Consistent with the effect of reduc-
ing -catenin levels, the GSK-3 inhibitor BIO enhanced the
survival of 109Q/109Q cells (Fig. 4C) with no detectable change
in htt expression (Fig. 4D). This amelio-
ration of cell survival was accompanied by
increased -catenin expression (Fig. 4D)
and, consistently, was lost when 109Q/
109Q cells were incubated with BIO and
-catenin siRNA together (Fig. 4C).
Therefore, in both mouse and C. elegans
models for HD, -catenin has neuropro-
tective effects, and altering its dosage is
detrimental to neuronal cell survival.
Next, we explored the role of SIRTs
and UCPs on mouse striatal cell survival.
Reducing SIRT1 levels showed no effect
on cell survival (Fig. 4E). We tested
whether reducing levels of either SIRT2
and SIRT3, two additional sirtuin fam-
ily members, may modulate striatal cell
survival, and observed no effect as well.
Therefore, lowering these sirtuins did
not affect neuronal survival. Second, we
examined the two neuronal UCPs
(UCP2, UCP4). UCP2 siRNAs de-
creased the survival of 109Q/109Q cells
(Fig. 4E) with no change in htt expres-
sion (Fig. 4F), and they reduced UCP2
mRNA levels (Fig. 4G). In contrast,
UCP4 siRNAs increased the survival of
109Q/109Q cells (Fig. 4E) with no
change in htt expression (Fig. 4F), and
they reduced UCP4 mRNA levels (Fig.
4G), suggesting evolutionary diversity
for mouse UCP activity compared to the
sole UCP in C. elegans.
Next, we tested whether SIRT1 and
-catenin might cooperate in the modu-
lation of mouse striatal cell survival since
sir-2.1/SIRT1 and bar-1/-catenin are
linked tomodulate neuron dysfunction in
128Q nematodes. To this end, we overex-
pressed SIRT1 either alone or in combina-
tion with -catenin siRNA. The
overexpression of SIRT1 slightly en-
hanced the survival of 109Q/109Q cells
subjected to serum deprivation with no change in htt levels (Fig.
5A,B). As observed previously, reducing -catenin levels was
strongly detrimental to 109Q/109Q cell survival (Fig. 5A), and
this effect was suppressed by SIRT1 overexpression, suggesting
that raising SIRT1 levels can compensate for the detrimental ef-
fect of -catenin reduction, which further connected the SIRT1
and -catenin pathways. We then examined further the individ-
ual effects of SIRT1 and -catenin in mouse striatal cells. Given
that UCP gene expressionmay be regulated by FOXO proteins as
suggested by previous studies (Lee et al., 2003; Paik et al., 2009),
we tested for the effects of -catenin reduction and SIRT1 over-
expression on the expression levels of UCP2 and UCP4. In mu-
tant htt striatal cells, reducing -catenin, which aggravates cell
death vulnerability, increased mRNA levels of UCP4 (detrimen-
tal to cell survival), whereas SIRT1 overexpression, which is
slightly neuroprotective, had the opposite effect (Fig. 5C). Con-
versely, reducing -catenin decreased mRNA levels of UCP2 (a
neuroprotective gene) in mutant htt cells, with however no sig-
nificant effect of SIRT1 overexpression (Fig. 5C). These results
indicated that while SIRT1 and -catenin may have common
Figure 5. Effects of-catenin and SIRT1 in mutant htt striatal cells from HdhQ111mice. A, Mutant htt cells showed increased
susceptibility to cell death induced by serum deprivation (***p  0.001 compared to 7Q/7Q). SIRT1 overexpression slightly
enhanced the survival of 109Q/109Q striatal cells with no effects in 7Q/7Q cells (**p 0.01 compared to untreated 109Q/109Q).
Reducing-catenin enhanced themortality of 109Q/109Q striatal cells with no effects in 7Q/7Q cells (***p 0.001 compared to
untreated 109Q/109Q). When SIRT1 overexpression was combined with -catenin reduction in 109Q/109Q striatal cells, the
detrimental effect of reducing-catenin was compensated by SIRT1 overexpression (N (number of experiments performed) 3
with SD; ***p 0.001 compared to -catenin reduction). n.s., Not significant. B, Representative Western blots showing that
striatal cells transfected with the SIRT1 construct (an active variant lacking an internal segment in the N terminus) have increased
SIRT1 levels. n.a., Not applicable. C, Effects of reducing-catenin or overexpressing SIRT1 on the expression levels of UCP2. The
expression of theUCP4gene is downregulated by-catenin siRNAwith no effect by SIRT1 overexpression (O/E) in 109Q/109Q cells
(N 4with SD; *p 0.05). No effectwas detected in 7Q/7Q cells. ns, Not significant. Scramble RNA (-catenin) showedno effect
on the UCP2/UCP4 gene expression levels (C, D).
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effects such as the repression of UCP4 levels, they may differ in
their ability to promote UCP2 levels.
Collectively, these results were consistent with a well docu-
mented model in which the FOXO, SIRT1, and -catenin pro-
teins may form a complex in the nucleus to regulate gene
expression in nematodes and other species (Brunet et al., 2004).
Further, these results highlighted a cross-talk between -catenin
and SIRT1 in the regulation of vulnerability to cell death caused
by mutant htt expression, which may be primarily mediated by
modulating the levels of UCP4, a UCP detrimental to mutant htt
cell survival.
Discussion
The Sir2/SIRT1 gene and its target daf-16/FOXOhave emerged as
potent protective factors for HD and other degenerative diseases
(Morley et al., 2002; Parker et al., 2005; Cohen et al., 2006; Kim et
al., 2007; Jeong et al., 2011; Jiang et al., 2011). Since FOXO inte-
grates numerous signals and regulates the expression of many
genes (Greer and Brunet, 2008; Landis andMurphy, 2010; Yen et
al., 2011), an essential question is how the FOXO network pro-
tectsHDneurons. Does it play a role in the early phases ofmutant
htt toxicity such as neuronal dysfunction and vulnerability to cell
death?
Our data show that -catenin, SIRT1, and UCPs may partic-
ipate in the regulation of vulnerability to cell death of mutant htt
striatal cells, which is consistent with the protective effect of in-
creased sir-2.1 dosage against neuron dysfunction in 128Q nem-
atodes, an effect that requires daf-16/FOXO (Parker et al., 2005),
the FOXO cofactor bar-1/-catenin (Essers et al., 2005), and
ucp-4, which we suggest to be a DAF-16 regulated gene. As sum-
marized in Figure 6, these results are consistent with a previously
proposed model in which the SIRT1, FOXO, and -catenin pro-
teins may form a complex in the nucleus to regulate gene expres-
sion in nematodes and other species (Tissenbaum and Guarente,
2001; Brunet et al., 2004; Essers et al., 2005; Berdichevsky et al.,
2006; Wang et al., 2006). Importantly, neuroprotective effects of
SIRT1 activation were recently reported in several mouse models
of HD (Jeong et al., 2011; Jiang et al., 2011), and FOXO3a acety-
lation may be involved in SIRT1 protection (Jiang et al., 2011),
which corroborates theC. elegans data. In addition, neuroprotec-
tive effects of -catenin were consistently observed in expanded-
polyQ nematodes and mutant htt striatal cells. However, we
observed differences between C. elegans and mouse striatal cells
for UCP activity. This is expected, as evolutionary diversity in
gene family function is a widely observed phenomenon. The
UCPs can have profound effects on neurons with chronic uncou-
pling, promoting mitochondrial biogenesis and elevated ATP
levels (Andrews et al., 2005b). The enhancement of 128Q toxicity
in nematode ucp-4mutants suggests that ucp-4 normally protect
neurons from the dysfunction induced by expanded polyQ ex-
pression. However, for mouse striatal cells that express mutant
htt, while UCP4 may normally contribute to their vulnerability,
UCP2 may protect from it. This is consistent with the neuropro-
tective effect of UCP2 overexpression in mouse models of Par-
kinson’s disease (Andrews et al., 2005a).While theC. elegans and
mouse striatal cell model both emphasized the neuroprotective
effects of -catenin, they showed differences in their ability to
account for the cross-talk between Sir2/SIRT1 and -catenin.
Expanded polyQ nematodes indicated that bar-1/-catenin is re-
quired for sir-2.1/SIRT1 overexpression to be neuroprotective.
However, mutant htt striatal cells poorly recapitulated the neu-
roprotective effects of SIRT1 overexpression and primarily indi-
cated that SIRT1 overexpression compensates for the detrimental
effect of -catenin reduction.
These results highlight the complexity of the regulation
around FOXO factors (Greer and Brunet, 2008; Landis andMur-
phy, 2010; Yen et al., 2011), and they illustrate how the conclu-
sions about the role of cell survival genesmay be influenced by the
methodological and cellular context in which their activity is as-
sessed. For example, SIRT1was reported to deacetylate-catenin
and suppress its ability to activate transcription in mammalian
cells (Firestein et al., 2008), which appears to contrast with our
findings. However, this study was performed in human colon
cancer cell lines, where SIRT1--catenin homeostasis may be
different compared to neurons and cells expressing expanded
polyQs. In addition, several studies have indicated that-catenin
is an important survival factor in normal (Essers et al., 2005) and
diseased (Inestrosa and Arenas, 2010) cells through its ability to
coactivate either TCF (T-cell factor) or FOXO transcription fac-
tors. However, a study of neuronal cell death inHDhas suggested
that abnormal accumulation of -catenin may cause neurotox-
icity (Godin et al., 2010). Since -catenin is neuroprotective
against the early phases of mutant polyQ cytotoxicity (neuron
dysfunction, cell vulnerability), this suggests that -catenin ho-
meostasis and activity may change along the pathogenic process
in HD.
Finally, the activation of cell survival mechanisms controlled
by FOXO factors may contribute to delaying HD pathogenesis.
Our data indeed suggest that GSK-3 inhibitors require the
FOXO network for protecting neurons from the dysfunction in-
duced by expanded polyQs, suggesting that GSK-3 may have
potential for the treatment of HD. In conclusion, our data reveal
that neuroprotection by sirtuin sir-2.1 from expanded polyQs
requires-catenin and ucp-4 inC. elegans, suggesting that FOXO
interactors modulate the early phases of mutant polyQ cytotox-
icity. Our findings raise the possibility that FOXO interactors
Figure 6. Workingmodel for the role of bar-1/-catenin, daf-16/FOXO and sir-2.1/SIRT1 in
the regulation ofmutant polyglutamine neuron homeostasis. The effects observed in C. elegans
andmouse striatal cells, twomodels of the early cytotoxicity/cell-vulnerability induced bymu-
tant htt, are summarized in the context of prior knowledge on the binding of BAR-1/-catenin
to DAF-16/FOXO (Essers et al., 2005) and the role of GSK-3/-catenin and SIRT1 in the modu-
lation of FOXO activity in the nucleus and its ability to regulate gene expression (Greer and
Brunet, 2008; Landis and Murphy, 2010; Yen et al., 2011). Genes required for neuroprotection
by sir-2.1 in C. elegans as previously reported (Parker et al., 2005) or indicated herein are
underlined. Bold indicates gene activity in mouse striatal cells as suggested by the ability of
SIRT1 overexpression to compensate for the detrimental effect of reducing -catenin on cell
survival, and by the effects on UCP2 expression levels.
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might have a role in themodification of the pathogenic process in
HD, and this will be addressed in future studies.
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